Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status

Fig. 3

Survival analysis using the Kaplan-Meier method. a Median progression-free survival (PFS) of patients without VM was 279 days, compared was 167 days in patients with VM (log-rank test, P < 0.001). b In the no-VM group, the PFS of chemotherapy was 257 days (8.6 months) compared with 313 days (10.4 months) for TKIs (log-rank test, P < 0.001). c In the VM group, the PFS of chemotherapy was 137 days (4.6 months) compared with 178 days (5.9 months) for TKIs (log-rank test, P = 0.199)

Back to article page